Hamburg - Delayed Quote EUR

NOVARTIS AG N (NOT.HM)

97.21

-1.99

(-2.01%)

As of 8:01:12 AM GMT+2. Market Open.

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Galmed Pharmaceuticals (GLMD), 6,307% surge in interest CG Oncology (CGON), 3,377% surge in interest Chemomab Therapeutics (CMMB), 3,029% surge in interest BioCardia (BCDA), 1,244% surge in interest Senti Biosciences (SNTI), 1,175% surge in interest Tevogen Bio Holdings (TVGN), 332% surge in interest Regulus Therapeutics (RGLS), 223% surge in interest Spr

TipRanks 5 days ago

NVS

NVSEF

RGLS
Novartis to Acquire Regulus in $1.7 Billion Deal

With the merger, the Swiss pharmaceutical company aims to bring to more patients farabursen, a kidney-disease treatment developed by Regulus.

The Wall Street Journal 7 days ago

NVS

NVSEF

RGLS
Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics with a focus on autosomal dominant polycystic kidney disease (ADPKD), a severe renal diseaseLead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial Transaction includes USD 0.8 billion upfront with a potential additional USD 0.9 billion payment upon the achievement of a future regulatory milestone;

GlobeNewswire 7 days ago

NVS

NVSEF
Novartis Scores A Beat-And-Raise Quarter — And Shares Make A Break For A Buy Point

Novartis stock made a break for a buy point Tuesday after the drugmaker beat first-quarter expectations and raised its full-year outlook.

Investor's Business Daily 7 days ago

NVS

NVSEF
Novartis Lifts Guidance After Profit, Sales Top Views

Novartis raised its 2025 outlook after its core operating profit rose 23% on year, boosted by strong demand for its key drugs.

The Wall Street Journal 8 days ago

NVS

NVSEF
Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1

Ad hoc announcement pursuant to Art. 53 LRNet sales grew +15% (cc1, +12% USD) with core operating income1 up +27% (cc, +23% USD) Sales growth driven by continued strong performance from Entresto (+22% cc), Kisqali (+56% cc), Kesimpta (+43% cc), Cosentyx (+18% cc), Leqvio (+72% cc) and Scemblix (+76% cc) Core operating income margin1 reached 42.1%, +400 basis points (cc), mainly driven by higher net sales Operating income grew +44% (cc, +38% USD); net income up +37% (cc, +34% USD)Core EPS1 grew +

GlobeNewswire 8 days ago

NVS

NVSEF
Stocks to watch this week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

Earnings preview of key companies reporting next week and what to look out for.

Yahoo Finance UK 12 days ago

VSCFF

GBPEUR=X

GBP=X
Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a major U.S. investment. The $200 billion pharma company intends to invest $23 billion in U.S.-based manufacturing to conduct research and development and produce all its major drugs stateside. Judging by Novartis’ stock performance in the days following the news, the market signaled its approval. Donald Trump is likely to be delighted, too. Novartis’ latest move is a reactiv

TipRanks 22 days ago

LLY

NVS

NVSEF
Novartis Stock Rises After Swiss Drugmaker Promises to Boost U.S. Manufacturing

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 billion over the next five years to expand its footprint in the U.S. The company said it will establish a research hub in San Diego, expand three U.S. plants and build six new ones. The investment will create roughly 1,000 new jobs at Novartis, and lead to around 4,000 other jobs in the U.S. outside of Novartis, the company said.

The Wall Street Journal 25 days ago

NVS

NVSEF
Swiss Drugmaker Novartis Promises to Boost U.S. Manufacturing Amid Tariff Threats

A Swiss drug giant has gotten the message from President Trump’s tariff threats. Novartis said Thursday it will spend $23 billion over the next five years to expand its footprint in the U.S. The company said it will establish a research hub in San Diego, expand three U.S. plants and build six new ones. The investment will create roughly 1,000 new jobs at Novartis, and lead to around 4,000 other jobs in the U.S. outside of Novartis, the company said.

The Wall Street Journal 26 days ago

NVS

NVSEF
Novartis to spend $23B to expand in the US

Novartis (NVS) announced that it plans to spend $23 billion to expand its manufacturing and research and development facilities in the US. The company says the move will create "approximately 4,000 additional US jobs." To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.

Yahoo Finance Video 26 days ago

NVS

NVSEF
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

The latest investor updates on stocks that are trending on Wednesday.

Yahoo Finance UK 28 days ago

DAL

GM

SVNDF
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Novartis today announced the US Food and Drug Administration (FDA) has granted accelerated approval for Vanrafia® (atrasentan), a potent and selective endothelin A (ETA) receptor antagonist, for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. This is generally defined as a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g1. Vanrafia is a once-daily, non-steroidal, oral treatment that can be added onto supportive care,

PR Newswire last month

NVS

NVSEF
Big Pharma Avoids Worst-Case Tariff Scenario

Drugmakers breathed a sigh of relief Wednesday after President Trump didn’t announce pharmaceutical tariffs. Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce. Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won’t be hit by any other tariff provisions, such as the 10% “baseline” tariff.

The Wall Street Journal last month

JNJ

NVS

NVSEF
Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

After nearly seven years as a member of the Executive Committee of Novartis (ECN), Klaus Moosmayer will pursue his next chapter of leadership outside of NovartisKaren Hale to drive the next phase of enterprise alignment for our Legal and ERC functions Basel, March 31, 2025 – Novartis announced today the appointment of Karen Hale to the expanded role of Chief Legal and Compliance Officer for Novartis, effective April 14, 2025. She will continue to report to Vas Narasimhan, M.D., CEO of Novartis a

GlobeNewswire last month

NVS

NVSEF
FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Ad hoc announcement pursuant to Art. 53 LR New indication approximately triples eligible patient population, allowing Pluvicto® to be used after one androgen receptor pathway inhibitor (ARPI) and now before chemotherapyPluvicto significantly reduced risk of progression or death by 59% and more than doubled median radiographic progression-free survival (rPFS) vs. change in ARPI in Phase III PSMAfore trial*Approximately half of patients do not live long enough to receive a second treatment for mCR

GlobeNewswire last month

NVS

NVSEF
Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Long-term disability and safety data from ALITHIOS open-label extension study on continuous treatment with Kesimpta vs. later switch from teriflunomide in relapsing multiple sclerosis (RMS) patients to be presentedAdditional presentations highlight the Novartis neuroscience pipeline, including remibrutinib for RMS and iptacopan for generalized myasthenia gravisBasel, March 25, 2025 – Novartis will present data from studies across its neuroscience portfolio, including seven-year disability outcom

GlobeNewswire last month

NVS

NVSEF
Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

Morgan Stanley analyst Judah Frommer notes that Novartis (NVS) has received FDA approval for Fabhalta for C3G. The label comes with a few important restrictions/caveats that leave room for Apellis’s (APLS) Empaveli to differentiate itself. The firm highlights that Fabhalta is indicated for adults with C3G, and is indicated to reduce proteinuria. Moreover, the label explicitly states that outcomes have not been established in post-transplant patients. Morgan Stanley says that overall, the restric

TipRanks last month

NVS

NVSEF

APLS
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis today announced that oral Fabhalta® (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce proteinuria, making it the first and only treatment approved for this condition1-4.

PR Newswire last month

NVS

NVSEF
New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA Treatment with investigational OAV101 IT led to statistically significant 2.39-point improvement on the HFMSE vs. 0.51 points in sham control armSafety findings were consistent in both treatment-naïve and treatment-experienced patientsThese new data indicate the potential for OAV101 IT to be a clinically meaningful treatment option for a broa

GlobeNewswire last month

NVS

NVSEF

Performance Overview

Return	NOT.HM	MSCI WORLD (^990100-USD-STRD)
YTD	+35.58%	-0.89%
1-Year	+35.58%	+8.69%
3-Year	+48.10%	+33.43%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

NOVARTIS AG N (NOT.HM)

Biotech Alert: Searches spiking for these stocks today

Novartis to Acquire Regulus in $1.7 Billion Deal

Novartis to acquire Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD, the most common genetic cause of renal failure

Novartis Scores A Beat-And-Raise Quarter — And Shares Make A Break For A Buy Point

Novartis Lifts Guidance After Profit, Sales Top Views

Novartis continues strong momentum with double-digit sales growth, robust margin expansion and multiple approvals in Q1

Stocks to watch this week: Apple, Microsoft, Shell, HSBC, Lloyds and AstraZeneca

Novartis (NVS) Unleashes $23BN Strategic Investment Masterstroke

Novartis Stock Rises After Swiss Drugmaker Promises to Boost U.S. Manufacturing

Swiss Drugmaker Novartis Promises to Boost U.S. Manufacturing Amid Tariff Threats

Novartis to spend $23B to expand in the US

Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca

Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)

Big Pharma Avoids Worst-Case Tariff Scenario

Novartis appoints Karen Hale, Chief Legal and Compliance Officer, as Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer, steps down from the Executive Committee of Novartis

FDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer

Novartis to present new data at AAN, including seven-year disability outcomes and safety analysis of Kesimpta® in people with relapsing multiple sclerosis

Morgan Stanley says Fabhalta’s label leaves opportunity for Apellis’ Empaveli

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA

Performance Overview